We are live on ! Find out more
PVCT

Provectus Biopharmaceuticals
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

43 hedge funds and large institutions have $3.83M invested in Provectus Biopharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

10% more funds holding

Funds holding: 39 → 43 (+4)

0.42% less ownership

Funds ownership: 5.22% → 4.8% (-0.42%)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

68% less capital inflows, than outflows

Capital inflows: $194K | Capital outflows: $608K

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
5
Reduced
10
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

PVCT Hedge Fund Activity: Q4 2015 in Review

43 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Provectus Biopharmaceuticals (PVCT) for Q4 2015, worth a combined $3.83M — down 38% from $6.13M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new PVCT positions and 4 closed out — a net gain of 5 holders — while 5 added to existing stakes and 10 trimmed.

The largest buyer was Vanguard Group, adding an estimated $48.4K. The largest seller was Goldman Sachs, cutting an estimated $280K.

  • 43 institutional investors held Provectus Biopharmaceuticals (PVCT) as of Q4 2015, up from 39 in Q3 2015.
  • Funds reported $3.83M of Provectus Biopharmaceuticals stock for Q4 2015, down 38% quarter-over-quarter.
  • 9 funds opened new Provectus Biopharmaceuticals positions in Q4 2015 and 4 closed out, a net change of +5 holders.
  • The largest Provectus Biopharmaceuticals buyer in Q4 2015 was Vanguard Group, an estimated $48.4K added.
  • The largest Provectus Biopharmaceuticals seller in Q4 2015 was Goldman Sachs, an estimated $280K sold.

Based on aggregated 13F filings for Q4 2015.